For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Tafamidis and Tafamidis meglumine represents a true change. These groundbreaking therapies stabilize the transthyretin protein, slowing its destructive build-up and lessening the burden